Treatment of non-small cell lung cancer with a combination of 3-amino-3-(1-methyl-1h-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-22,44-dicarbonitrile and an egfr-tki
OwnerFrancis BURROWS, Shivani MALIK +1inventors
InventorsFrancis BURROWS, Shivani MALIK, Hetika VORA
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of using a compound of Formula (I), or a pharmaceutically acceptable form thereof, optionally in combination with an EGFR inhibitor, such as osimertinib, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing non-small cell lung carcinoma (NSCLC).
Claims52
A method of mitigating EGFR-TKI resistance in a subject, comprising administering to the subject (a) a compound of Formula (I):
- or a pharmaceutically acceptable form thereof, and (b) an EGFR-TKI.
A method of preventing or delaying emergence of EGFR-TKI resistance in a subject, comprising administering to the subject (a) a compound of Formula (I):
- or a pharmaceutically acceptable form thereof, and (b) an EGFR-TKI;
- wherein the subject is an EGFR-TKI-naïve subject.
A method of treating non-small cell lung cancer (NSCLC) in a subject, comprising administering to the subject (a) a compound of Formula (I):
- or a pharmaceutically acceptable form thereof, and (b) an EGFR-TKI.
Dependencies are inferred from the claim text.